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Summary Objectives: To characterize by molecular techniques Burkholderia
strains responsible for respiratory tract infections in cystic fibrosis (CF) patients
(children and adults), to assign the Burkholderia cepacia complex (Bcc) isolates
to a genomovar and to assess the presence of cblA and esmR genes in bacteria. Un-
ique or sequential Burkholderia isolates (n¼ 48) that had been collected from eight
CF children and 17 adults over several (4e6) years were investigated; moreover 11
reference strains were analyzed.
Methods: The microorganisms were identified by using biochemical methods, gen-
otyped by pulse field gel electrophoresis (PFGE) and random-amplified polymorphic
DNA fingerprintingePCR (RAPDePCR), and assessed by PCR assays for the genomo-
var and cblA and esmR genes of Bcc.
Results: Among isolates 70.8% were identified as Bcc genomovar III-A; one child was
infected by Burkholderia ambifaria and four adults were colonized with Burkhol-
deria gladioli. The cblA gene was not detected in any of the isolates, while the
esmR gene was detected in the 52.1% of the strains, all belonging to genomovar
III-A.
Conclusion: Molecular analysis of strains revealed in CF patients a colonization with
a persistent Burkholderia flora with strains of one genotype. The prevalence of Bcc
of genomovar III-A in the two categories of patients and of B. gladioli in four adults
demonstrated that transmission may have occurred between subjects. Moreover
the B. ambifaria infection demonstrated in a child may be environmentally derived.
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Burkholderia species are widely distributed in
the natural environment and several species
also cause disease.1 Correct identification of
this genus is difficult, but recently2 a recA
gene-based approach was developed to identify
the entire Burkholderia genus. In this genus,
closely related species, referred collectively to
the Burkholderia cepacia complex (Bcc), are rec-
ognized as opportunistic human pathogens that
cause numerous outbreaks, particularly among
cystic fibrosis (CF) patients. They cause a rapid
decline in pulmonary function, with ensuing in-
creased morbidity and mortality.3 Because only
a limited number of antibiotics are effective
against Bcc, complete eradication of infection
is rare.4
Taxonomic studies based on traditional pheno-
typic and genotypic tests5e8 have demonstrated
that Bcc includes nine genomic species or ge-
nomovars: B. cepacia (formerly genomovar I),
Burkholderia multivorans (genomovar II), Bur-
kholderia cenocepacia (genomovar III, divided
into four recA clusters, III-A, III-B, III-C and
III-D), Burkholderia stabilis (genomovar IV),
Burkholderia vietnamiensis (genomovar V), Bur-
kholderia dolosa (genomovar VI), Burkholderia
ambifaria (genomovar VII), Burkholderia anthina
(genomovar VIII) and Burkholderia pyrrocinia
(genomovar IX).
Various markers have been associated with
transmissible strains of Bcc, such as the cblA and
esmR genes, which encode the protein for cable
pilus production and the B. cepacia epidemic strain
marker BCESM.9,10
With these recent developments in genotyping
techniques, we examined 48 Burkholderia strains
isolated from eight CF children and 17 adults
(over the last 4 and 6 years, respectively). These
subjects were admitted to hospital for periodic
controls in two different centres, one in the city
of Torino (northwest Italy), the other located in
Torino city outskirts. Moreover 11 reference strains
were assessed.
The strains identified as belonging to the Bur-
kholderia genus by using biochemical methods
were analyzed by the followings: (I) genotyping
was effected by pulsed-field gel electrophoresis
(PFGE) and random-amplified polymorphic DNA
fingerprintingePCR (RAPDePCR); (II) the genomo-
var of Bcc was assessed by PCR assays; and (III)
the cblA and esmR genes of Bcc were detected
by PCRs.Materials and methods
Patients and bacterial strains
The 48 clinical (unique or sequential) isolates were
obtained from the expectorates of eight children
affected by CF attending the Cystic Fibrosis Centre
of the Regina Margherita Hospital (Torino, Italy)
and 17 adults with CF attending the Cystic Fibrosis
Centre at S. Luigi Gonzaga Hospital in Orbassano
(Torino, Italy), centres that arew15 km apart. The
reference Bcc strains examined were ATCC 17759
(Bcc genomovar I), kindly given by C. Van Pelt (Rot-
terdam), LMG 17588 (Bcc genomovar II), 13011
(Bcc genomovar III-B), 18888 (Bcc genomovar IV),
16232 (Bcc genomovar V), 18941 (Bcc genomovar
VI), 19467 (Bcc genomovar VII), 16670 (Bcc ge-
nomovar VIII) and 14191 (Bcc genomovar IX), ob-
tained from BCCM/LMG bacteria collection (Gent,
Belgium), the strain CF5610 (Bcc genomovar III-A,
cblAþ ET12 lineage strain, from John Govan’s col-
lection, Edinburgh, kindly sent by F. Clode, PHLS,
London). Moreover the LMG 2216 strain (B. gladioli)
was assessed.
Bacteria were plated on OFPBL agar (Bectone
Dickinson) and on Mu¨eller Hinton agar (Oxoid) and
liquid cultures effected in Trypticase Soy Broth
(Oxoid) at 28 C for 48 h; the isolates were tenta-
tively identified as Bcc using commercial tests,
including API 20NE kit (BioMe`rieux) and Vitek
Auto Microbic System (BioMe`rieux).
Pulsed-field gel electrophoresis (PFGE)
DNA macrorestriction and PFGE of Burkholderia
strains were carried out as previously described11
with some modifications. Bacteria were incubated
in Trypticase Soy Broth, then centrifuged at
3000 rpm for 10 min; the pellet was washed in
1 ml of SE buffer (25 mM EDTA, 75 mM NaCl, pH
7.4), resuspended in 150 ml of the same buffer
and diluted. The bacterial suspension was included
in 150 ml 2% low melting point agarose (Bio-Rad) in
SE buffer; agarose plugs were prepared and main-
tained at 4 C. Bacteria were lysed by incubating
the plugs in lysis solution containing 0.5 mgml1
proteinase K (Sigma), 0.5 M EDTA, 1% N-laurylsarco-
sine (Sigma) for 16 h at 37 C. Plugs were washed
six times by gentle agitation for 1 h in TE buffer
and stored in TE buffer at 4 C, then incubated
three times in 1 ml of pre-XbaI buffer (6 mM
TrisHCl, 150 mM NaCl, 6 mM MgCl2, 1 mM DTT, pH
7.9) for 30 min at 37 C and treated overnight at
37 C with 10 U XbaI (SigmaeAldrich). The gel was
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(Bio-Rad) in 0.5 TBE buffer (45 mM Triseborate
and 1 mM EDTA) and sealed with 0.75% low melting
point agarose. A 50e1000 Kb molecular weight
marker (Sigma) was used. PFGE was performed
using the CHEF Mapper XA System (Bio-Rad). The
gel run was performed at 6.0 V cm1 for 23 h at
14 C with initial time pulse of 1 s and final time
pulse of 30 s. Gel images of the genomic DNAs
were digitized by using a Kodak Image Station
2000R following ethidium bromide staining. The
clonality was examined according to the recom-
mendations12; i.e., isolates differing in more than
six bands were considered sufficiently divergent
to warrant separate pattern designations, whereas
those that differ by one to three (aec subtypes) or
four to six bands should be considered, respective-
ly, closely or possibly related. Reproducibility was
checked by repeating PFGE runs.
Random-amplified polymorphic DNA (RAPD)
Template DNAwas prepared from bacteria grown for
48 h at 28 C on Mu¨eller Hinton agar plates. Crude
DNA extracts were obtained by suspending five colo-
nies in 100 ml sterile distilled water, vortexing, cen-
trifuging at 3000 rpm for 5 min and using the
supernatant. We used primers 208, 270 and 272 (5#-
ACGGCCGACC-3#; 5#-TGCGCGCGGG-3#; and 5#-AGC
GGGCCAA-3#, respectively) and the conditions de-
scribed.13 The amplified DNA fragments were sepa-
rated in a 1.5% agarose gel (Invitrogen) in 1 TBE
with 0.5% ethidium bromide (10 mgml1, Sigma) for
1 h and 40 min at 6 V cm1. RAPD fingerprints were
analyzed by Kodak Image Station 2000R and the clon-
ality was evaluated based on guidelines reported.14
Isolates that differed by two or more prominent
bandswereassignedtodifferentmajor types,where-
as isolates that differed by one to two faint bands
were considered minor variant types (a and b) of a
given major type. Reproducibility of the random
PCR patterns was assessed by repeating PCR runs.
PCR analysis
The identification of the Burkholderia genomovar
status was effected by PCR using nine recA primer
pairs specific for genomovars I, II, III-A, III-B, IV, V,
VI, VII and VIII.5e8 For isolates whose identification
remained unclear, the evaluation of 23S rDNA of
the species B. gladioli by using the SS-PCR with
primer pair LP1eLP415 was done. Detection by
PCRs of the B. cepacia epidemic strain marker
(BCESM) and cable pili subunit gene (cblA) was
carried out as previously described.9,10Results
The analysis effected to determine the species or
genomovar status ofBurkholderia revealed (Table 1)
that among the 48 isolates tested 34 (11 from seven
children and 23 from 13 adults) belonged to B. ceno-
cepacia group III-A, one strain (sequentially isolated
from a child) was identified as B. ambifaria (ge-
nomovar VII), and 11 strains, obtained from four
adults, were negative for all Bcc genomovars and
positive to the PCR analysis for B. gladioli. Among
all strains 25, four from children and 21 from adults,
belonging exclusively to B. cenocepacia group III-A,
were positive for esmR gene (Table 1); on the con-
trary, no strain was cblA-positive. By PFGE (Table 1,
Fig. 1) we observed that the isolates show four dis-
tinct banding patterns: P1, P2 (including four sub-
types), P3 and P4 (including P4a, that differed in
one band). The pattern indicated as P2 was the
most prevalent (75 and 58.8% of the bacteria col-
lected on the first occasion of microbiological diag-
nosis from children and adults, respectively). The
P1 and P3 profiles were noted only in strains from
adults, while one, indicated as not classified (NC)
because resulted not digested with XbaI, was iso-
lated from one child alone; strains characterized
as belonging to the P4 profile were observed in
few isolates. The results of RAPD analysis reported
were obtained using the primer 272, chosen after
test screening with primers 208, 270 and 272. Four
banding profiles were obtained by the analysis of
isolates: R1, R2 (including two subtypes, differing
in one to twominor bands), R3 andR4; the RAPDpro-
file designated as R2was prevalent andpresent both
in children and adults (Table 1, Fig. 1). The Burkhol-
deria strains with patterns P2eR2 corresponded to
B. cenocepacia group III-A, those not classified
(NC) by PFGE and defined as R3 by RAPD belonged
to B. ambifaria (genomovar VII), and those named
P1eR1 belonged to the B. gladioli species. The ref-
erence Bcc strain group III-A (CF5610) also revealed
a P2eR2 profile, whereas the other reference
strains tested, belonging to different Bcc genomo-
vars, had PFGE and RAPD patterns different from
the isolates tested (not reported) except for the
LMG 19467 strain (Bcc genomovar VII) whose RAPD
profile was similar to the isolate of the same ge-
nomovar collected from a child (Table 1).
Discussion
The poor prognosis of CF is especially associated
with an early onset of respiratory tract infection
with a variety of bacterial species. Among these are
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Category of patients
(number of strains)
Patients or
isolates
Isolation BCESM Species or
genomovar
status
PFGE profile RAPD
profile
Children (14) 1c I (02/96)  III-A P2b R2
II (10/96)  III-A P2d R2b
III (02/98) þ III-A P2c R2b
IV (10/98)  III-A P2d R2
V (06/99)  III-A P2d R2
2c I (10/96) þ III-A P2c R2a
3c I (01/00)  VII NCa R3
II (03/00)  VII NCa R3
III (05/00)  VII NCa R3
4c I (02/00) þ III-A P2a R2b
5c I (10/98)  III-A P2d R2b
6c I (02/96)  III-A P4 R3
7c I (10/96) þ III-A P2a R2a
8c I (11/96)  III-A P2 R2
Adults (34) 1a I (04/99)  B. gladioli P1 R1
II (07/00) B. gladioli P1 R1
III (07/01)  B. gladioli P1 R1
IV (01/03)  B. gladioli P1 R1
V (09/04)  B. gladioli P1 R1
VI (02/05)  B. gladioli P1 R1
2a I (10/00) þ III-A P2d R2
II (04/03) þ III-A P2c R2
3a I (04/99)  B. gladioli P1 R1
II (02/05)  B. gladioli P1 R1
4a I (/03/99)  III-A P4a R3
5a I (06/99) þ III-A P2a R2a
II (05/01) þ III-A P2a R2a
III (04/03) þ III-A P2a R2a
6a I (07/99)  B. gladioli P1 R1
II (01/05)  B. gladioli P1 R1
7a I (07/00) þ III-A P3 R4
8a I (08/00) þ III-A P2a R2a
9a I (11/00) þ III-A P2d R2b
II (06/01) þ III-A P2d R2b
III (02/02) þ III-A P2a R2b
IV (02/03) þ III-A P2a R2a
V (02/05) þ III-A P2d R2b
10a I (09/99)  B. gladioli P1 R1
11a I (09/99)  III-A P4a R3
12a I (01/02) þ III-A P2a R2
II (11/02) þ III-A P2 R2
13a I (11/04) þ III-A P2b R2
14a I (11/04) þ III-A P2a R2
II (02/05) þ III-A P2a R2
15a I (11/04) þ III-A P2b R2
II (01/05) þ III-A P2b R2
16a I (01/05) þ III-A P2d R2
17a I (01/05) þ III-A P2a R2
a NC, not classified because not restricted with XbaI enzyme.included several species of the genus Burkholderia
whose incidence appears to be increasing; of
the emerging pathogens, Bcc and B. gladioli, as
also demonstrated in the present work, areprominent.16 Between these microorganisms there
is a high degree of phenotypic similarity and accu-
rate identification is difficult. The use of a procedure
based on a species-specific PCR for the identification
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Figure 1 B. cepacia complex isolated from CF patients. (a) PFGE profiles of XbaI-digested genomic DNA. M: 50e
1000 kb molecular weight marker (Sigma). From line 1 to 12: P2a, P2, P2d, P2d, P2a, P2a, P2c, P4, P2a, P2d, P3
and P1 profiles, respectively. (b) RAPD main profiles. M: molecular weight marker (Step Ladder 50 bp, Sigma).
From line 1 to 12: R1, R1, R2, R2, R1, R2a, R4, R4, R2b, R3, R2a and R2 profiles, respectively.of B. gladioli15 is useful to clarify the role of this
microorganism as a human pathogen in CF.
Our results revealed that B. cenocepacia (ge-
nomovar III-A) is the most prevalent (70.8 and 80%
of all isolates or of the firstly examined strain for pa-
tient, respectively) in the samples obtained fromCF
patients. This is in line with other data derived from
the analysis of CF patients,13,17e24 but different
from results reported in a Belgian study.25 There is
evidence that genomovar III-A strains aremore inva-
sive for respiratory epithelial cells and associated
with greater morbidity and mortality.26 Eleven
strains (isolated from four different adults), that
by biochemical analysis were presumptively identi-
fied as B. cepacia, resulted positive to the PCR assay
for B. gladioli and revealed particular PFGE and
RAPD patterns. These results confirm previous ob-
servations27 indicating that B. gladioli is the species
most frequently misidentified by commercial sys-
tems as Bcc and show that this species may
determine adverse clinical outcome and person-
to-person transmission. Moreover one child was col-
onized by B. ambifaria (genomovar VII); infection
with this species, which is common in environmen-
tal samples, has not been previously reported, to
our knowledge, in strains isolated from other Italian
patients,18e21 though found in small number in
patients of other countries.22,28e30 This suggests
that this species may play a role as a human patho-
gen and its acquisition from the environment is
possible.Following up some patients over certain time
period obtaining different isolates per patient, we
noted that in all cases the infection was persis-
tent. Only little genetic differences were identi-
fied in sequential isolates of some patients (1c and
9a); this fact might be due to antibiotic resistance
variations. The PFGE and RAPD profiles P3eR4 and
P4eR3 noted in singular isolates from four patients
might be derived from isolates harbouring more
than one Burkholderia strain or hybrids between
Bcc and B. gladioli, as previously reported.31
Many Bcc genomovar III-A strains, isolated from
patients submitted to controls in two different
hospitals, were genotypically similar to the refer-
ence epidemic (ET 12 lineage) strain belonging to
the same genomovar and associated with serious
outbreaks among CF patients in UK. However, in
the isolates tested the cblA gene was not demon-
strated, perhaps owing to the instability of its se-
quence.18 Isolates with a P2eR2 DNA profile and
positive for esmR gene (part of a genomic cluster
encoding virulence and metabolism-associated
gene32) prevailed, suggesting the possibility of in-
terpersonal transmission or nosocomial acquisi-
tion. CF patients may acquire other Bcc lineages
also from the environment. In recent years, in
fact, Bcc has been used in agriculture in biopesti-
cides and bioremedial products,1 most notably
particular strains of B. vietnamiensis and B. ambi-
faria because of their low incidence of isolation
from CF patients.33
164 T. Allice et al.Strategies introduced in different countries
have limited the epidemic spread of Bcc17,34,35;
so the implementation of stringent infection con-
trol measures is important to limit spread both
within and outside hospital and epidemiological
studies of Burkholderia species are critical to
keep pace with the ecological and pathogenic in-
terest in the genus.
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